Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesVivos Therapeutics Inc

Vivos Therapeutics Inc

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
0.0937 USD -0.01 ( 8.67%)
Last update at 2026-11-06T21:00:00Z
VOLUME
752377
Market Cap
6.78M

Momentum Score

…

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.09
Low
0.11
High
52 Week Price Range
1.96
Low
48.79
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Vivos Therapeutics, Inc. develops non-surgical oral appliances and treatment protocols intended to address sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea, marketed through a network of trained dental providers. Long-term growth could be driven by rising sleep apnea awareness, demand for CPAP alternatives, provider network expansion and improved reimbursement, which may appeal to investors focused on device-based solutions in a large underserved market.

Key risks include uncertain clinical adoption and reimbursement, regulatory or litigation exposure, competition from CPAP and other therapies, and execution and financing risk given the company's small size.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.10
Dividend Yield
-
Revenue TTM
13.36M
Revenue Per Share
8.63
Gross Profit TTM
12.60M
Debt / Equity
4.85
ROE
-413.02%
Net Debt
0.35M
ROCE
-727.43%
Diluted EPS TTM
-11.05

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -23.84M -20.29M -12.06M -10.75M -8.44M
Net income -22.66M -20.29M -8.82M -10.89M -8.54M
Selling general administrative 29.04M 25.79M 16.09M 16.17M 9.27M
Selling and marketing expenses 5.34M 5.55M 2.31M 2.31M 1.16M
Gross profit 10.02M 12.60M 10.41M 8.66M 2.71M
Reconciled depreciation 0.67M 0.73M 0.72M 0.75M 0.61M
Ebit -25.03M -19.47M -8.71M -10.58M -8.34M
Ebitda -24.46M -18.63M -11.24M -9.80M -7.73M
Depreciation and amortization 0.57M 0.84M -2.53M 0.77M 0.61M
Operating income -25.03M -19.47M -8.71M -10.58M -8.34M
Other operating expenses 41.05M 36.36M 21.78M 21.97M 12.13M
Interest expense 1.19M 0.01M 0.10M 0.14M 0.10M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income - 0.12M 0.08M 0.02M 0.00M
Net interest income 0.00M 0.10M -0.02M -0.12M -0.10M
Income tax expense -1.19M 0.01M -3.23M 0.14M 0.10M
Total revenue 16.02M 16.89M 13.07M 11.39M 3.79M
Total operating expenses 35.05M 32.08M 19.12M 19.23M 11.05M
Cost of revenue 6.00M 4.28M 2.65M 2.74M 1.08M
Total other income expense net 1.19M -0.82M -3.35M -0.18M -0.10M
Net income from continuing ops -23.84M -20.29M -12.06M -10.75M -8.44M
Net income applicable to common shares - -20.29M -17.99M -11.75M -9.44M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 10.73M 13.72M 33.69M 25.33M 7.55M
Intangible assets 0.42M 0.30M 0.34M 0.27M 0.69M
Other current assets 0.62M 1.45M 1.57M 0.67M 0.30M
Total liab 10.32M 8.92M 8.15M 8.41M 10.49M
Total stockholder equity 0.41M 4.80M 25.54M 16.92M -2.94M
Other current liab 2.53M 2.06M 2.86M 1.74M 1.35M
Common stock - 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -93.05M -79.47M -55.62M -35.33M -23.28M
Other liab - - 0.64M 0.16M 0.08M
Good will 2.84M 2.84M 2.84M 2.67M 2.67M
Other assets - - 0.36M 1.12M 1.07M
Cash 1.64M 3.52M 24.03M 18.21M 0.47M
Total current liabilities 7.29M 6.81M 7.51M 7.82M 9.09M
Current deferred revenue 2.14M 2.93M 2.40M 2.94M 2.95M
Net debt 0.35M -1.11M -22.40M -16.92M 3.24M
Short term debt 0.47M 0.42M 1.33M 0.87M 3.71M
Short long term debt - - 1.26M 0.87M 3.71M
Short long term debt total 2.00M 2.41M 1.63M 1.29M 3.71M
Other stockholder equity 93.46M 84.27M 81.16M 52.25M 20.33M
Property plant equipment - - 2.83M 0.87M 1.14M
Total current assets 2.46M 5.42M 27.32M 20.39M 1.98M
Net tangible assets - - 22.36M 13.98M -6.30M
Net receivables 0.20M 0.46M 1.72M 1.52M 0.96M
Long term debt - - - 0.42M -
Inventory 0.00M - -0.52M - 0.26M
Accounts payable 2.15M 1.41M 0.92M 2.28M 1.08M
Accumulated other comprehensive income - - - - -0.50M
Common stock total equity - - - 0.00M 0.00M
Non currrent assets other 0.31M 0.37M 0.36M 1.12M 1.07M
Non current assets total 8.27M 8.30M 6.37M 4.93M 5.57M
Capital lease obligations 2.00M 2.41M 0.37M - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.92M -2.61M -0.12M 0.09M -1.12M
Change to liabilities - -0.40M -0.28M 2.61M 1.13M
Total cashflows from investing activities - -2.61M -0.12M 0.09M -1.12M
Net borrowings - -0.03M 1.19M 3.73M -0.09M
Total cash from financing activities 0.00M 24.17M 23.54M 4.47M 5.25M
Change to operating activities - 0.20M 0.41M 0.20M 0.27M
Net income -23.84M -20.29M -12.06M -10.75M -8.44M
Change in cash -20.51M 5.82M 17.74M -0.79M -1.18M
Begin period cash flow 24.03M 18.21M 0.47M 1.25M 2.43M
End period cash flow 3.52M 24.03M 18.21M 0.47M 1.25M
Total cash from operating activities -19.59M -15.73M -5.68M -5.34M -5.31M
Issuance of capital stock 0.00M 27.93M 24.74M 1.25M 6.35M
Depreciation 0.67M 0.73M 0.72M 0.75M 0.61M
Other cashflows from investing activities - 0.01M 0.01M 0.01M 0.01M
Dividends paid - - 3.72M 3.76M -
Change to inventory - 0.17M 0.33M 0.40M -
Change to account receivables 0.75M 0.23M -0.56M -0.28M -0.53M
Sale purchase of stock 0.00M -1.50M -2.15M -0.35M -1.00M
Other cashflows from financing activities -0.92M -2.24M 7.19M 7.36M -0.01M
Change to netincome - 3.79M 6.09M 2.12M 1.57M
Capital expenditures 0.92M 2.40M 0.12M 0.18M 1.25M
Change in working capital 1.71M 0.03M -0.43M 2.53M 0.87M
Stock based compensation 2.40M 2.66M 2.17M 1.99M 1.28M
Other non cash items -0.52M -0.01M 3.92M 0.08M 0.36M
Free cash flow -20.51M -18.13M -5.80M -5.52M -6.56M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
VVOS
Vivos Therapeutics Inc		 -0.01
8.67%		 0.09 - - 0.57 18.94 0.59 -0.49
ABT
Abbott Laboratories		 -0.03
0.03%		 109.93 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC		 -3.04
2.90%		 101.80 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation		 -9.21
2.75%		 325.87 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG		 -2.15
4.12%		 49.85 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Vivos Therapeutics Inc

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.

7921 Southpark Plaza, Littleton, CO, United States, 80120

844 672 4357

https://www.vivos.com

114

Name Title Year Born
Mr. R. Kirk Huntsman Co-Founder, Chairman & CEO 1958
Mr. Bradford K. Amman CFO, Treasurer & Sec. 1962
Mr. Todd Huntsman Co-Founder & Sr. VP of Product and Technology NA
Ms. RaeAnn Byrnes Co-Founder and Sr. VP of Events & Clinical Advisory Services NA
Ms. Susan McCullough Co-Founder & Exec. VP NA
Ms. Julie Gannon Chief of Staff & Investor Relations NA
Mr. Nicholas M. DeGennaro Sr. VP of the Medical Integration Division NA
Ms. Ruth Hembree Sr. VP of Practice Services NA
Ms. Stephanie Huebner Sr. VP of DSO Operations NA
Mr. R. Kirk Huntsman Co-Founder, Chairman of the Board & CEO 1958

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…